First Eagle Investment Management LLC raised its position in Threshold Pharmaceuticals Inc. (NASDAQ:THLD) by 86.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,974,802 shares of the biotechnology company’s stock after buying an additional 2,775,369 shares during the period. First Eagle Investment Management LLC owned 0.08% of Threshold Pharmaceuticals worth $4,048,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of THLD. Oxford Asset Management raised its stake in shares of Threshold Pharmaceuticals by 746.7% in the second quarter. Oxford Asset Management now owns 202,522 shares of the biotechnology company’s stock worth $129,000 after buying an additional 178,602 shares during the period. Paloma Partners Management Co purchased a new stake in shares of Threshold Pharmaceuticals during the second quarter worth $152,000. Finally, Deerfield Management Co. bought a new position in Threshold Pharmaceuticals during the second quarter valued at approximately $1,641,000. 27.04% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Threshold Pharmaceuticals (NASDAQ:THLD)

Threshold Pharmaceuticals Inc. (NASDAQ:THLD) traded down 2.5253% on Wednesday, hitting $0.4825. The stock had a trading volume of 842,489 shares. The company has a market cap of $34.53 million, a P/E ratio of 0.8015 and a beta of 4.78. The firm’s 50-day moving average is $0.44 and its 200-day moving average is $0.63. Threshold Pharmaceuticals Inc. has a 52-week low of $0.21 and a 52-week high of $3.78.

Threshold Pharmaceuticals (NASDAQ:THLD) last issued its quarterly earnings data on Monday, November 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. Equities research analysts anticipate that Threshold Pharmaceuticals Inc. will post ($0.36) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Financial Market News and is owned by of Financial Market News. If you are reading this piece on another site, it was illegally stolen and republished in violation of US & international copyright legislation. The legal version of this piece can be read at

Several research analysts have recently commented on the company. S&P Equity Research reduced their price target on Threshold Pharmaceuticals from $0.67 to $0.52 in a research report on Friday, September 30th. William Blair reissued an “outperform” rating on shares of Threshold Pharmaceuticals in a research report on Monday, October 3rd.

Threshold Pharmaceuticals Company Profile

Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

5 Day Chart for NASDAQ:THLD

Want to see what other hedge funds are holding THLD? Visit to get the latest 13F filings and insider trades for Threshold Pharmaceuticals Inc. (NASDAQ:THLD).

Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.